ESALF - Biogen risks activist pressure if FDA rejects Alzheimer's therapy: report

Wall Street has turned its attention on Biogen ([[BIIB]] +0.4%) ahead of the FDA action date on June 07 for the experimental Alzheimer’s therapy aducanumab co-developed by the company in partnership with Eisai ([[ESALF]]).Without sufficient preparation for a patent cliff for three multiple sclerosis drugs—Tysabri, Tecfidera, and Vumerity — Biogen remains vulnerable to the activist incursion, Insightia analyst Iuri Struta argues, according to Fierce Pharma.In its Activist Insight Vulnerability study, Insightia places Biogen in the 93rd percentile among the companies most vulnerable to activist pressure over the next nine months.With aducanumab being the “only real hope of avoiding a plunge over the patent cliff,” rejection from the FDA could hasten the activist pressure, according to the Insightia report.Meanwhile, in a note to clients, UBS analysts Colin Bristow and the team cites an expert raising his estimate to 60% probability of approval up from 30% in April.That could rise to 90%

For further details see:

Biogen risks activist pressure if FDA rejects Alzheimer’s therapy: report